Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of KK4277 in healthy volunteers and patients with systemic or cutaneous lupus erythematosus
jRCT2071220015Phase 1Completed
- Sponsor
- Kyowa Kirin
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) comparing KK4277 with Placebo (2 arms). Primary endpoint: Number of participants with adverse events. Started Jul 2022; status: completed.
02
Drugs
KK-4277
03
Conditions
systemic lupus erythematosus (SLE)cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on jRCT2071220015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220015.